Insider Trading March 26, 2026

Saba Capital boosts holdings in Virtus Dividend Fund with $732,111 purchase

Hedge fund executes two-day buy of 58,171 NFJ shares, raising its position to 10,021,861 shares

By Derek Hwang NFJ
Saba Capital boosts holdings in Virtus Dividend Fund with $732,111 purchase
NFJ

Saba Capital Management, L.P., a reported ten-percent holder of the Virtus Dividend, Interest & Premium Strategy Fund (NYSE: NFJ), purchased 58,171 shares across two trades on March 24-25, 2026. The acquisitions, executed at prices between $12.45 and $12.64, total $732,111 and bring Saba's stake to 10,021,861 shares.

Key Points

  • Saba Capital Management, L.P. bought 58,171 shares of Virtus Dividend, Interest & Premium Strategy Fund (NYSE: NFJ) in two transactions on March 24-25, 2026.
  • The purchases were executed at $12.45 and $12.64 per share, totaling $732,111, and increased Saba's holding to 10,021,861 shares.
  • The disclosures affect the financial and asset management sectors by documenting a material block trade by a significant shareholder in an investment fund.

Saba Capital Management, L.P. increased its stake in the Virtus Dividend, Interest & Premium Strategy Fund (NYSE: NFJ) through two purchases totaling 58,171 shares, according to a Form 4 filing with the Securities and Exchange Commission.

The transactions occurred over two consecutive days. On March 24, 2026, Saba Capital acquired 16,685 shares at $12.45 per share. The following day, March 25, 2026, the firm bought an additional 41,486 shares at $12.64 per share. Aggregate consideration for the two trades was $732,111.

Following these purchases, Saba Capital Management, L.P. now holds 10,021,861 shares of the Virtus Dividend, Interest & Premium Strategy Fund. The filing identifies Saba Capital as a ten-percent owner of the fund. The Form 4 provides the transaction-level details - share counts, per-share prices, dates and the resulting total position - without additional commentary from the filer.

This report presents the recorded transaction data as disclosed to the SEC. The filing documents the precise number of shares acquired and the per-share prices for each trade, and it records the firm’s updated holding in the fund.


Transaction details

  • March 24, 2026 - 16,685 shares purchased at $12.45 per share.
  • March 25, 2026 - 41,486 shares purchased at $12.64 per share.
  • Total shares acquired - 58,171. Total value - $732,111.
  • Post-transaction holdings for Saba Capital Management, L.P. - 10,021,861 shares.

Context and limits of the filing

The Form 4 filing provides an official record of the two transactions and the updated holding level, but it does not supply motives, forward-looking intent, or commentary from Saba Capital. The disclosure conveys the transactional facts reported to the SEC; it does not offer additional information on strategy, timing beyond the trade dates, or any planned future activity.

Readers should note that the filing itself is a snapshot of ownership and recent trades and does not include any further explanation from the reporting party.

Risks

  • The Form 4 filing records the trades and the updated position but does not state Saba Capital’s intent or any plans for further buying or selling - uncertainty for investors in the financial sector.
  • The filing provides no commentary on timing or strategy behind the purchases, leaving unclear whether these trades reflect a tactical or strategic change in holdings - potential uncertainty for asset managers and market participants.
  • Information in the filing is limited to transaction details and holdings; it does not include any forward-looking guidance or rationale, which constrains interpretation of the purchase’s implications for the fund or markets.

More from Insider Trading

Spyre Therapeutics CFO Disposes $370K in Stock, Exercises Options Same Day as Trial Timelines Accelerate Apr 3, 2026 Fold Holdings CEO completes modest stock sale to cover RSU tax obligations Apr 3, 2026 Spyre Therapeutics CEO Executes $739,912 Stock Sale as Trials Accelerate Apr 3, 2026 Spyre Therapeutics CMO Sells Shares, Exercises Options as Trials Accelerate Apr 3, 2026 Fold CFO Sells Small Stake to Meet Tax Withholding as Company Faces Revenue Shortfall Apr 3, 2026